ER-positive early-stage breast cancer is associated with risk for late recurrence (more than 5 years after diagnosis). Considering all subtypes of breast cancer, most recurrences occur within the first 5 years after diagnosis. In triple-negative breast cancer, most recurrences happen within 3 years after diagnosis.
Tamoxifen does reduce the risk for recurrence after diagnosis of hormone receptor–positive breast cancer.
Learn more about breast cancer recurrence risk.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Elwyn C. Cabebe, Stefania Morganti. Fast Five Quiz: The Recurrence Risks for Breast Cancer - Medscape - Feb 06, 2023.